LifeStance Health Group (NASDAQ:LFST) Stock Price Expected to Rise, JPMorgan Chase & Co. Analyst Says

Key Points

• JPMorgan raised its price target on LifeStance to $15 from $13 but kept a neutral rating, implying 3.72% upside from the current share price.
• Analyst sentiment overall is more positive: MarketBeat reports a “Moderate Buy” consensus and an average target price of $14, based on one Strong Buy, six Buy, and four Hold ratings.
• LifeStance beat quarterly estimates, reporting EPS of $0.06 versus $0.04 expected and revenue of $455.86 million versus $431.59 million; revenue grew 25.3% year over year.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) had its target price raised by equities researchers at JPMorgan Chase & Co. from $13.00 to $15.00 in a note issued to investors on Thursday, Benzinga reports. The brokerage presently has a "neutral" rating on the stock. JPMorgan Chase & Co.'s target price suggests a potential upside of 3.72% from the company's current price.

Several other research firms have also recently commented on LFST. BTIG Research raised their price target on shares of LifeStance Health Group from $18.00 to $20.00 and gave the stock a "buy" rating in a report on Thursday, November 5th. Barclays upped their price objective on shares of LifeStance Health Group from $13.00 to $15.00 and gave the company an "overweight" rating in a research note on Thursday, September 10th. Canaccord Genuity Group increased their target price on shares of LifeStance Health Group from $15.00 to $16.00 and gave the stock a "buy" rating in a research report on Friday, November 6th. Weiss Ratings reissued a "hold (c)" rating on shares of LifeStance Health Group in a research note on Wednesday, November 4th. Finally, KeyCorp boosted their price target on shares of LifeStance Health Group from $15.00 to $17.00 and gave the company an "overweight" rating in a report on Friday, November 6th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat, LifeStance Health Group currently has an average rating of "Moderate Buy" and an average target price of $14.00.

LifeStance Health Group Stock Up 0.6%

NASDAQ:LFST opened at $14.46 on Thursday. The stock's fifty day moving average is $12.74 and its two-hundred day moving average is $9.60. The stock has a market capitalization of $5.50 billion, a price-to-earnings ratio of 76.12 and a beta of 1.35. The company has a quick ratio of 1.44, a current ratio of 1.44 and a debt-to-equity ratio of 0.17. LifeStance Health Group has a 52 week low of $6.01 and a 52 week high of $15.66.

LifeStance Health Group (NASDAQ:LFST - Get Free Report) last announced its quarterly earnings data on Thursday, November 5th. The company reported $0.06 EPS for the quarter, topping analysts' consensus estimates of $0.04 by $0.02. LifeStance Health Group had a return on equity of 4.82% and a net margin of 4.29%. The firm had revenue of $455.86 million during the quarter, compared to analyst estimates of $431.59 million. The firm's revenue was up 25.3% compared to the same quarter last year. Research analysts anticipate that LifeStance Health Group will post 0.18 EPS for the current year.

Insider Activity

In related news, CTO Vukasin Paunovich sold 42,067 shares of the business's stock in a transaction that occurred on Wednesday, September 2nd. The stock was sold at an average price of $12.87, for a total value of $541,402.29. Following the completion of the sale, the chief technology officer owned 205,379 shares of the company's stock, valued at approximately $2,643,227.73. The trade was a 17.00% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 3.50% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On LifeStance Health Group

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. KBC Group NV bought a new stake in LifeStance Health Group in the first quarter worth approximately $29,000. IFP Advisors Inc increased its holdings in shares of LifeStance Health Group by 316.5% during the 2nd quarter. IFP Advisors Inc now owns 3,694 shares of the company's stock valued at $40,000 after acquiring an additional 2,807 shares during the last quarter. EverSource Wealth Advisors LLC increased its holdings in shares of LifeStance Health Group by 359.1% during the 1st quarter. EverSource Wealth Advisors LLC now owns 6,909 shares of the company's stock valued at $44,000 after acquiring an additional 5,404 shares during the last quarter. PNC Financial Services Group Inc. raised its stake in shares of LifeStance Health Group by 615.3% in the 1st quarter. PNC Financial Services Group Inc. now owns 9,285 shares of the company's stock valued at $59,000 after acquiring an additional 7,987 shares in the last quarter. Finally, Assetmark Inc. lifted its holdings in LifeStance Health Group by 17.0% in the 1st quarter. Assetmark Inc. now owns 9,419 shares of the company's stock worth $60,000 after purchasing an additional 1,367 shares during the last quarter. Institutional investors own 85.50% of the company's stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc. is a U.S. provider of outpatient mental health services. The company offers care through in-person clinics and virtual appointments, connecting patients with behavioral health professionals. Its services include psychotherapy, psychiatric evaluations and medication management. LifeStance's clinicians treat a range of mental health conditions, including anxiety, depression, attention-deficit/hyperactivity disorder and mood disorders. Founded in 2017, LifeStance has expanded its network across the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.